Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 6, 2005, Pages 844-849

  Shin, Jung Woo ^a   Chung, Young Hwa ^a   Choi, Min Hee ^a   Kim, Jeong A ^a   Ryu, Soo Hyung ^b   Jang, Myoung Kuk ^a   Kim, In Sook ^a   Park, Neung Hwa ^a   Lee, Han Chu ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Lamivudine; Precore mutation; Viral breakthrough

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ABDOMINAL PAIN; ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DEMOGRAPHY; DIARRHEA; DRUG TOLERABILITY; FATIGUE; FEMALE; GENDER; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNORADIOMETRIC ASSAY; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; STATISTICAL ANALYSIS; STOP CODON; VIRUS CORE; VIRUS MUTATION; WILD TYPE;

EID: 21244450305     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03824.x     Document Type: Article

References (25)

1. Doong S-L, Tsai C-H, Schinazi RF et al. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl Acad. Sci. USA 1991; 88: 8495-9.
2. Chang CN, Skalski V, Zhou JH et al. Biochemical pharmacology of (+) and (-) 2′, 3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem. 1992; 267: 22. 414-20.
3. Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J. Med. Virol. 2000; 61: 398-402.
4. Tassopoulos NC, Volpes R, Pastore G et al. the Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-96.
5. Santantonio T, Mazzola M, Iacovazzi T et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. 2000; 32: 300-6.
6. Hadziyannis SJ, Papatheodoridis GV, Dimou E et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-51.
7. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-34.
8. Dienstag JL, Perrillo RP, Schiff ER et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995; 333: 1657-61.
9. Lai C-L, Chien R-N, Leung NWY et al. The Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998; 339: 61-8.
10. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082-7.
11. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256-63.
12. Nowak MA, Bonhoeffer S, Hill AM et al. Viral dynamics in hepatitis B virus infection. Proc. Natl Acad. Sci. USA 1996; 93: 4398-402.
13. Zeuzem S, de Man RA, Honkoop P et al. Dynamics of hepatitis B virus infection in vivo. J. Hepatol. 1997; 27: 431-6.
14. Kaneko S, Miller RH, Di Bisceglie AM et al. Detection of hepatitis B virus DNA in serum by polymerase chain reaction. Application for clinical diagnosis. Gastroenterology 1990; 99: 799-804.
15. Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promotor variants. J. Viral Hepat. 2002; 9: 52-61.
16. Lindh M, Horal P, Dhillon AP et al. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J. Viral Hepat. 2000; 7: 258-67.
17. Tsugeno H, Yamada G, Kinoshita M et al. Quantitative analysis of wild-type and precore mutant hepatitis B virus in carriers. Hepatol. Res. 2002; 23: 48-54.
18. Brunetto MR, Stemler M, Schodel E et al. Identification of HBV variants which cannot produce pre-core derived HBeAg and may be responsible for severe hepatitis. Ital. J. Gastroenterol. 1989; 21: 151-4.
19. Garman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of e antigen in patients with chronic HBV infection. Lancet 1989; 2: 588-91.
20. Carman W, Thomas H, Domingo E. Viral genetic variation: hepatitis B virus as a clinical sample. Lancet 1993; 341: 349-53.
21. Liaw Y-F, Leung NWY, Chang T-T et al. The Asia Hepatitis Lamivudine Study Group. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-80.
22. Lok ASF, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145-53.
23. Yuen M-F, Sablon E, Hui C-K et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-91.
24. Cho SW, Hahm K-B, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32: 1163-9.
25. Lok ASF, Ankara US, Green S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pregenome encapsidation signal. Proc. Natl Acad. Sci. USA 1994; 91: 7077-81.